EverPoint Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

EverPoint Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-200,000	Closed	-$3.05M	–	543
2016 Q3	$3.05M	Sell	200,000 -100,000	-33%	-$4.04M	0.05%	307
2016 Q2	$11.6M	Sell	300,000 -350,000	-54%	-$12.6M	0.23%	127
2016 Q1	$18.1M	Buy	650,000 +350,000	+117%	+$11.7M	0.36%	66
2015 Q4	$16.1M	Buy	300,000 +75,000	+33%	+$3.78M	0.34%	87
2015 Q3	$9.01M	Sell	225,000 -75,000	-25%	-$2.45M	0.23%	131
2015 Q2	$9.59M	Buy	300,000 +80,000	+36%	+$2.03M	0.18%	178
2015 Q1	$5.25M	Buy	+220,000	New	+$4.93M	0.1%	265

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's ITCI Position: Q4 2016 in Review

EverPoint Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 200,000 shares — an estimated $3.05M sold.

EverPoint Asset Management first reported a position in ITCI in Q1 2015 and held it in 7 quarters. The position peaked at $18.1M in Q1 2016. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

EverPoint Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
EverPoint Asset Management sold 200,000 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $3.05M.
EverPoint Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2015 and held it in 7 quarters.
EverPoint Asset Management's Intra-Cellular Therapies Inc. position peaked at $18.1M in Q1 2016.
129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.